Which has stronger earnings and valuation, RADX or CELZ?

Creative Medical Technology has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $1.88M 11.86 -$37.43M N/A N/A Creative Medical Technology $10K 623.68 -$5.99M -$2.07 N/A

Is RADX or CELZ more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Creative Medical Technology N/A -86.52% -81.96%

Do analysts recommend TCRX or CELZ?

TScan Therapeutics currently has a consensus price target of $2.67, indicating a potential upside of 732.03%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe TScan Therapeutics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to TCRX or CELZ?

In the previous week, TScan Therapeutics had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 3 mentions for TScan Therapeutics and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.10 beat TScan Therapeutics' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Creative Medical Technology 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CELZ or ESLA?

Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 1,609.40%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CELZ or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% Estrella Immunopharma N/A N/A -328.72%

Do analysts recommend CELZ or ATOS?

Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 768.95%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is CELZ or ATOS more profitable?

Creative Medical Technology's return on equity of -86.52% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% Atossa Genetics N/A -102.99% -85.78%

Does the media prefer CELZ or ATOS?

In the previous week, Atossa Genetics had 2 more articles in the media than Creative Medical Technology. MarketBeat recorded 4 mentions for Atossa Genetics and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.10 beat Atossa Genetics' score of 0.19 indicating that Creative Medical Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Creative Medical Technology 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Genetics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CELZ or JSPR?

Jasper Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 1,197.48%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Is CELZ or JSPR more profitable?

Creative Medical Technology's return on equity of -86.52% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% Jasper Therapeutics N/A -884.17% -143.83%

Creative Medical Technology (CELZ) Competitors

$0.95 +0.00 (+0.50%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.94 -0.01 (-1.20%)

As of 10/2/2026 06:41 PM Eastern

Compare

CELZ vs. RADX, TCRX, ESLA, ATOS, and JSPR

Should you buy Creative Medical Technology stock or one of its competitors? Creative Medical Technology's main competitors and comparable companies include Radiopharm Theranostics (RADX), TScan Therapeutics (TCRX), Estrella Immunopharma (ESLA), Atossa Genetics (ATOS), and Jasper Therapeutics (JSPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Creative Medical Technology compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Radiopharm Theranostics currently has a consensus price target of $11.00, suggesting a potential upside of 674.65%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, equities analysts clearly believe Radiopharm Theranostics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Radiopharm Theranostics' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Creative Medical Technology	N/A	-86.52%	-81.96%

Radiopharm Theranostics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market.

Creative Medical Technology has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$1.88M	11.86	-$37.43M	N/A	N/A
Creative Medical Technology	$10K	623.68	-$5.99M	-$2.07	N/A

In the previous week, Creative Medical Technology had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Radiopharm Theranostics. Creative Medical Technology's average media sentiment score of 1.10 beat Radiopharm Theranostics' score of 0.10 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Creative Medical Technology	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.4% of Creative Medical Technology shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Creative Medical Technology beats Radiopharm Theranostics on 7 of the 13 factors compared between the two stocks.

How does Creative Medical Technology compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

In the previous week, TScan Therapeutics had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 3 mentions for TScan Therapeutics and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.10 beat TScan Therapeutics' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Creative Medical Technology	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TScan Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market.

TScan Therapeutics currently has a consensus price target of $2.67, indicating a potential upside of 732.03%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe TScan Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Creative Medical Technology has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Creative Medical Technology's return on equity of -86.52% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Creative Medical Technology	N/A	-86.52%	-81.96%

Creative Medical Technology has lower revenue, but higher earnings than TScan Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	2.10	-$129.77M	-$0.91	N/A
Creative Medical Technology	$10K	623.68	-$5.99M	-$2.07	N/A

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

TScan Therapeutics beats Creative Medical Technology on 10 of the 16 factors compared between the two stocks.

How does Creative Medical Technology compare to Estrella Immunopharma?

Creative Medical Technology (NASDAQ:CELZ) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Estrella Immunopharma's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Estrella Immunopharma	N/A	N/A	-328.72%

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Creative Medical Technology has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	623.68	-$5.99M	-$2.07	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

In the previous week, Creative Medical Technology had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Estrella Immunopharma. Creative Medical Technology's average media sentiment score of 1.10 beat Estrella Immunopharma's score of 0.91 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Creative Medical Technology	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Estrella Immunopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 1,609.40%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Creative Medical Technology has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Summary

Creative Medical Technology beats Estrella Immunopharma on 8 of the 12 factors compared between the two stocks.

How does Creative Medical Technology compare to Atossa Genetics?

Creative Medical Technology (NASDAQ:CELZ) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by insiders. Comparatively, 9.8% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Creative Medical Technology's return on equity of -86.52% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Atossa Genetics	N/A	-102.99%	-85.78%

Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 768.95%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Atossa Genetics had 2 more articles in the media than Creative Medical Technology. MarketBeat recorded 4 mentions for Atossa Genetics and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 1.10 beat Atossa Genetics' score of 0.19 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Creative Medical Technology	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atossa Genetics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Creative Medical Technology has a beta of 2.06, suggesting that its stock price is 106% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Creative Medical Technology has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	623.68	-$5.99M	-$2.07	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

Summary

Creative Medical Technology beats Atossa Genetics on 8 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to Jasper Therapeutics?

Creative Medical Technology (NASDAQ:CELZ) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Creative Medical Technology has a beta of 2.06, meaning that its share price is 106% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, meaning that its share price is 216% more volatile than the broader market.

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Creative Medical Technology has higher revenue and earnings than Jasper Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	623.68	-$5.99M	-$2.07	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

Creative Medical Technology's return on equity of -86.52% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Jasper Therapeutics	N/A	-884.17%	-143.83%

Jasper Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 1,197.48%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Creative Medical Technology had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for Creative Medical Technology and 0 mentions for Jasper Therapeutics. Creative Medical Technology's average media sentiment score of 1.10 beat Jasper Therapeutics' score of 0.68 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Positive
Jasper Therapeutics	Positive

Summary

Jasper Therapeutics beats Creative Medical Technology on 8 of the 14 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELZ vs. The Competition

Export

Metric	Creative Medical Technology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.24M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-0.46	13.00	274.71	26.04
Price / Sales	623.68	1,288.64	656.46	105.13
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.46	16.57	10.93	6.31
Net Income	-$5.99M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-8.12%	-2.97%	-2.00%	-1.66%
1 Month Performance	-14.74%	-10.82%	-6.19%	-4.68%
1 Year Performance	-70.70%	19.00%	8.03%	1.57%

Creative Medical Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELZ Creative Medical Technology	1.6033 of 5 stars	$0.95 +0.5%	N/A	-70.7%	$6.24M	$10K	N/A	4	Positive News
RADX Radiopharm Theranostics	2.1818 of 5 stars	$1.52 -6.2%	$11.00 +623.7%	-77.1%	$23.86M	$1.88M	N/A	14	News Coverage Gap Down
TCRX TScan Therapeutics	2.9911 of 5 stars	$0.31 -0.2%	$2.67 +749.3%	-84.8%	$21.28M	$10.32M	N/A	142	News Coverage Gap Up
ESLA Estrella Immunopharma	1.5885 of 5 stars	$0.47 +0.9%	$8.00 +1,598.5%	-64.3%	$20.49M	N/A	N/A	N/A	News Coverage Gap Down
ATOS Atossa Genetics	2.198 of 5 stars	$2.05 +4.9%	$20.33 +894.3%	-84.6%	$20.41M	N/A	N/A	14	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELZ) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Creative Medical Technology (CELZ) Competitors

CELZ vs. RADX, TCRX, ESLA, ATOS, and JSPR

How does Creative Medical Technology compare to Radiopharm Theranostics?

Summary

How does Creative Medical Technology compare to TScan Therapeutics?

Summary

How does Creative Medical Technology compare to Estrella Immunopharma?

Summary

How does Creative Medical Technology compare to Atossa Genetics?

Summary

How does Creative Medical Technology compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Creative Medical Technology (CELZ) Competitors

CELZ vs. RADX, TCRX, ESLA, ATOS, and JSPR

How does Creative Medical Technology compare to Radiopharm Theranostics?

Do analysts rate RADX or CELZ?

Is RADX or CELZ more profitable?

Which has more volatility and risk, RADX or CELZ?

Which has stronger earnings and valuation, RADX or CELZ?

Does the media refer more to RADX or CELZ?

Do insiders & institutionals believe in RADX or CELZ?

Summary

How does Creative Medical Technology compare to TScan Therapeutics?

Does the media refer more to TCRX or CELZ?

Which has more volatility and risk, TCRX or CELZ?

Do analysts recommend TCRX or CELZ?

Is TCRX or CELZ more profitable?

Which has stronger earnings and valuation, TCRX or CELZ?

Do institutionals and insiders have more ownership in TCRX or CELZ?

Summary

How does Creative Medical Technology compare to Estrella Immunopharma?

Is CELZ or ESLA more profitable?

Do insiders & institutionals believe in CELZ or ESLA?

Which has preferable earnings & valuation, CELZ or ESLA?

Does the media prefer CELZ or ESLA?

Do analysts prefer CELZ or ESLA?

Which has more volatility and risk, CELZ or ESLA?

Summary

How does Creative Medical Technology compare to Atossa Genetics?

Do insiders & institutionals have more ownership in CELZ or ATOS?

Is CELZ or ATOS more profitable?

Do analysts recommend CELZ or ATOS?

Does the media prefer CELZ or ATOS?

Which has more volatility & risk, CELZ or ATOS?

Which has better earnings and valuation, CELZ or ATOS?

Summary

How does Creative Medical Technology compare to Jasper Therapeutics?

Which has more volatility and risk, CELZ or JSPR?

Do insiders and institutionals hold more shares of CELZ or JSPR?

Which has preferable earnings and valuation, CELZ or JSPR?

Is CELZ or JSPR more profitable?

Do analysts prefer CELZ or JSPR?

Does the media prefer CELZ or JSPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools